Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Lupin Q2 net profit drops 41.5 Percent to Rs 266 Crore

      Lupin Q2 net profit drops 41.5 Percent to Rs 266 Crore

      Medical Dialogues Bureau3 Nov 2018 10:11 AM IST
      New Delhi: Drug maker Lupin has recently reported a 41.5 per cent decline in its consolidated net profit at Rs 266 crore for the second quarter ended...
      Proteinx tied with Inbody to create awareness on  Muscle Health

      Proteinx tied with Inbody to create awareness on  Muscle Health

      Medical Dialogues Bureau3 Nov 2018 9:20 AM IST
      71% of Indians have Poor Muscle Health, 68% have low Protein levels – says InBody study in association with IPSOS. Poor muscle mass could lead to...
      Mercks Blockbuster Drug Keytruda Approved by FDA

      Merck's Blockbuster Drug Keytruda Approved by FDA

      Medical Dialogues Bureau3 Nov 2018 9:15 AM IST
      New Delhi: Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with...
      Novartis abandons effort for U.S. approval of biosimilar rituximab

      Novartis abandons effort for U.S. approval of biosimilar rituximab

      Medical Dialogues Bureau3 Nov 2018 9:10 AM IST
      According to analysts, Rituxan, a monoclonal antibody used in non-Hodgkin's lymphoma and rheumatoid arthritis, had more than $4 billion in sales in...
      Zydus Cadila gets USFDA Approval for Vardenafil Hydrochloride Tablets

      Zydus Cadila gets USFDA Approval for Vardenafil Hydrochloride Tablets

      Medical Dialogues Bureau2 Nov 2018 2:59 PM IST
      Ahmedabad: Zydus Cadila has launched Vardenafil Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg in the US market upon receiving the final...
      CCI approves IHH acquisition of Fortis Healthcare, Fortis Malar Hospital

      CCI approves IHH acquisition of Fortis Healthcare, Fortis Malar Hospital

      Medical Dialogues Bureau2 Nov 2018 2:48 PM IST
      In July, the board of Fortis Healthcare approved an Rs 4,000-crore offer from IHH Healthcare for buying 31.1 per cent stake in it. The proposal had...
      Strides Pharma Science to get Rs 147 Crore funding for consumer healthcare business

      Strides Pharma Science to get Rs 147 Crore funding for consumer healthcare business

      Medical Dialogues Bureau2 Nov 2018 11:57 AM IST
      The agreement also envisages Strides Consumer Pvt Ltd to become a fully owned subsidiary of Strides Global Consumer Healthcare Ltd at a later date,...
      Glenmark launches hair loss treatment Nourkrin in Russia

      Glenmark launches hair loss treatment Nourkrin in Russia

      Medical Dialogues Bureau2 Nov 2018 9:00 AM IST
      New Delhi: Glenmark Pharmaceuticals has recently announced the launch of Nourkrin, used to treat hair loss, in the Russian market.The product catering...
      Breaking: Madras HC STAY blocks online sale of medicines

      Breaking: Madras HC STAY blocks online sale of medicines

      Medical Dialogues Bureau1 Nov 2018 11:55 AM IST
      Purchasing medicines from unlicensed online stores can be risky as they may sell fake, expired, contaminated, unapproved drugs or otherwise unsafe...
      Aurobindo Pharma Issues Voluntary Recall of Irbesartan Drug: FDA

      Aurobindo Pharma Issues Voluntary Recall of Irbesartan Drug: FDA

      Medical Dialogues Bureau1 Nov 2018 10:15 AM IST
      New Delhi: Aurobindo Pharma Limited is voluntarily recalling 22 Batches of the drug substance Irbesartan due to the presence of an impurity,...
      FDC gets 8 observation from USFDA for Waluj plant

      FDC gets 8 observation from USFDA for Waluj plant

      Medical Dialogues Bureau1 Nov 2018 10:02 AM IST
      New Delhi: Drug firm FDC has received establishment inspection report (EIR) from the US health regulator for its Waluj plant. The company said it had...
      Dr Reddys Labs launches Atomoxetine Capsules in US Market

      Dr Reddy's Labs launches Atomoxetine Capsules in US Market

      Medical Dialogues Bureau1 Nov 2018 9:20 AM IST
      Hyderabad: Dr. Reddy’s Laboratories Ltd. has recently announced the launch of Atomoxetine Capsules, USP, a therapeutic equivalent generic version of...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok